Immunome (IMNM) Hisse Özeti

IMNM temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 87.3% daha düşük bir oranda işlem görüyor

Gelirin yılda 53.38% oranında artması öngörülüyor

Analistler hisse senedi fiyatının 54.5% oranında artacağı konusunda hemfikir

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Son 3 ayda önemli miktarda içeriden satış gerçekleşti

IMNM Community Fair Values

Create Narrative

See what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Immunome, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Immunome
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$23.00
52 Haftanın En Yüksek Seviyesi	US$27.65
52 Haftanın En Düşük Seviyesi	US$7.42
Beta	2.12
1 Aylık Değişim	6.14%
3 Aylık Değişim	-7.74%
1 Yıllık Değişim	189.67%
3 Yıllık Değişim	269.77%
5 Yıllık Değişim	29.65%
Halka arzdan bu yana değişim	71.00%

Son Haberler & Güncellemeler

Recent updates

Seeking Alpha • Jan 30

Immunome Can Take The Fight To Competitors With Varegacestat

Summary Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Varegacestat offers potential advantages, such as once-daily dosing, over SWTX's already-marketed drug for desmoid tumors, Ogsiveo. IMNM's announcement of a plan to offer $125M of common stock could provide a dip in the stock, but would provide more funds to develop its pipeline of antibody-drug conjugates. Read the full article on Seeking Alpha

Seeking Alpha • Dec 11

Immunome: A Recently Acquired Lead Asset And A Small Market

Summary Immunome's lead asset, AL102, is in a Phase 3 trial for desmoid tumors, showing promising ORR compared to the approved OGSIVEO. Immunome has a turbulent history, shifting focus from COVID-19 therapies to oncology, and acquiring AL102 from Ayala Therapeutics. Financially, Immunome has a market cap of $867mn and a cash runway of 4-5 quarters, risking dilution before drug launch. Despite the potential, IMNM's current market cap already reflects the risk-adjusted value of AL102, making it an avoid for now. Read the full article on Seeking Alpha

Seeking Alpha • Jan 18

Immunome: Why It Has Doubled Over The Last Month

Summary Immunome has experienced a meteoric rise in market capitalization without any pipeline drugs reaching clinical trials. The company's pipeline includes IM-1021, an antibody-drug conjugate targeting ROR1, and IM-4320, a monoclonal antibody targeting IL-38. IMNM's financial overview shows a cash runway of approximately 5 years, but the long wait time for clinical trials poses a significant risk. Read the full article on Seeking Alpha

Analiz Makalesi • Mar 17

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Nov 20

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Aug 05

Immunome GAAP EPS of -$0.74

Immunome press release (NASDAQ:IMNM): Q2 GAAP EPS of -$0.74. As of June 30, 2022, cash and cash equivalents totaled $34.6 million.

Analiz Makalesi • Aug 05

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Jun 30

Immunome gains 34% after preclinical data on COVID-19 antibody

Clinical-stage biotech Immunome (NASDAQ:IMNM) added ~34% on Thursday on the publication of research indicating that the company’s experimental three-antibody cocktail IMM-BCP-01 was effective against COVID-19 variants of concern including BA.1 and BA.2. IMM-BCP-01 consists of three patient-derived neutralizing antibodies, designed to target non-overlapping regions on the SARS-CoV-2 spike protein. According to results published in the journal science, IMM-BCP-01 was found to have decreased Omicron infection in the lungs of Syrian golden hamsters. The lab results have also indicated potential antiviral effector response, including phagocytosis, antibody-mediated cellular cytotoxicity, complement pathway activation. Results indicate that “IMM-BCP-01 could be a promising means for preventing or treating infection of SARS-CoV-2 variants of concern, including Omicron BA.1 and BA.2, in susceptible individuals,” researchers wrote. Early this month, Immunome (IMNM) announced the dosing initiation of an early-stage study for IMM-BCP-01 involving recently diagnosed COVID-19 patients. The topline data from the single dose, dose escalation study is expected in 2H 2022.

Analiz Makalesi • Feb 21

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analiz Makalesi • Oct 02

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Hissedar Getirileri

	IMNM	US Biotechs	US Pazar
7D	-1.4%	0.1%	2.6%
1Y	189.7%	35.5%	26.2%

Getiri vs. Endüstri: IMNM geçen yıl % 35.5 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: IMNM geçen yıl % 26.2 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is IMNM's price volatile compared to industry and market?
IMNM volatility
IMNM Average Weekly Movement	6.9%
Biotechs Industry Average Movement	10.7%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: IMNM son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: IMNM 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2006	177	Clay Siegall	immunome.com

Bir biyoteknoloji şirketi olan Immunome, Inc. antikor-ilaç konjugatlarının ve diğer onkoloji terapötiklerinin keşfi, tasarımı, geliştirilmesi, üretimi ve Amerika Birleşik Devletleri'nde ticarileştirilmesi faaliyetlerini yürütmektedir. Şirket, desmoid tümörlerin tedavisi için Faz 3 klinik çalışmasında olan bir gama sekretaz inhibitörü olan Varegacestat ve Faz 1 klinik çalışmasında olan bir reseptör tirozin kinaz benzeri yetim reseptör 1 antikor-ilaç konjugatı (ADC) olan IM-1021'i içeren klinik varlık geliştirmektedir. Ayrıca, fibroblast aktivasyon proteini hedefli bir radyoligand tedavisi olan IM-3050 ve IM-1617, IM-1340 ve IM-1335 gibi solid tümör ADC ilaç adayları da dahil olmak üzere preklinik varlıklar geliştirmektedir.

Immunome, Inc. Temel Bilgiler Özeti

Immunome'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IMNM temel i̇stati̇sti̇kler
Piyasa değeri	US$2.54b
Kazançlar(TTM)	-US$212.39m
Gelir(TTM)	US$6.94m

375.3x

P/S Oranı

-12.3x

F/K Oranı

IMNM aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IMNM gelir tablosu (TTM)
Gelir	US$6.94m
Gelir Maliyeti	US$177.29m
Brüt Kâr	-US$170.34m
Diğer Giderler	US$42.05m
Kazançlar	-US$212.39m

Son Raporlanan Kazançlar

Dec 31, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.88
Brüt Marj	-2,454.19%
Net Kâr Marjı	-3,059.99%
Borç/Özkaynak Oranı	0%

IMNM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/11 15:39
Gün Sonu Hisse Fiyatı	2026/05/11 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Immunome, Inc. 14 Bu analistlerden 13, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Adam Vogel	Craig-Hallum Capital Group LLC
Cory Kasimov	Evercore ISI
Salveen Richter	Goldman Sachs

Immunome (IMNM) Hisse Özeti

Ödüller

Risk Analizi

Immunome, Inc. Rakipler

Zai Lab

Arcus Biosciences

Aurinia Pharmaceuticals

Tango Therapeutics

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Immunome Files NDA for Varegacestat After Phase 3 Success in Desmoid Tumors

Immunome Inc Submits New Drug Application for Varegacestat for Treatment of Adults with Desmoid Tumors

Immunome, Inc., Annual General Meeting, Jun 09, 2026

Director recently sold US$1.3m worth of stock

Director notifies of intention to sell stock

Consensus revenue estimates decrease by 44%, EPS upgraded

Recent updates

Immunome Files NDA for Varegacestat After Phase 3 Success in Desmoid Tumors

Immunome Inc Submits New Drug Application for Varegacestat for Treatment of Adults with Desmoid Tumors

Immunome, Inc., Annual General Meeting, Jun 09, 2026

Director recently sold US$1.3m worth of stock

Director notifies of intention to sell stock

Consensus revenue estimates decrease by 44%, EPS upgraded

Full year 2025 earnings: EPS and revenues miss analyst expectations

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $400.4375 million.

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Price target increased by 25% to US$30.00

Third quarter 2025 earnings released: US$0.65 loss per share (vs US$0.78 loss in 3Q 2024)

New minor risk - Share price stability

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 118%

Price target decreased by 9.7% to US$24.50

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Immunome, Inc., Annual General Meeting, Jun 10, 2025

New minor risk - Share price stability

Consensus revenue estimates decrease by 41%, EPS upgraded

Chief Technical Officer recently bought US$104k worth of stock

Full year 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 12% to US$27.00

Immunome, Inc. Doses First Patient in Phase 1 Trial of IM-1021, A ROR1-Targeted ADC

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $150.000002 million.

Immunome Can Take The Fight To Competitors With Varegacestat

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

Immunome: A Recently Acquired Lead Asset And A Small Market

New minor risk - Share price stability

President recently bought US$962k worth of stock

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors At the European Society for Medical Oncology Congress 2024

Consensus revenue estimates increase by 21%, EPS downgraded

Price target decreased by 8.7% to US$30.60

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.